Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.

Hyperprolactinemia and Prolactinomas

Mancini, Tatiana, Casanueva, Felipe F., Giustina, Andrea · 2008 · Endocrinology and Metabolism Clinics of North America

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ecl.2007.10.013

Cites

157 of 157 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 42

  1. Bernichtein, 2001, S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist, Endocrinology, 142, 3950, 10.1210/endo.142.9.8369 · doi:10.1210/endo.142.9.8369
  2. Wu, 2003, Different biological effects of unmodified PRL and a molecular mimic of phosphorylated PRL involve different signaling pathways, Biochemistry, 42, 7561, 10.1021/bi034217s · doi:10.1021/bi034217s
  3. De Marinis, 2000, Effects of galanin on growth hormone and PRL secretion in anorexia nervosa, Metabolism, 49, 155, 10.1016/S0026-0495(00)91091-6 · doi:10.1016/s0026-0495(00)91091-6
  4. Lafuente, 2005, Toxic effects of cadmium on the regulatory mechanism of dopamine and serotonin on PRL secretion in adult male rats, Toxicol Lett, 155, 87, 10.1016/j.toxlet.2004.08.011 · DOI
  5. Niu, 2004, Neurobehavioral functions, serum PRL and plasma renin activity of manganese-exposed workers, Int J Immunopathol Pharmacol, 17, 17, 10.1177/03946320040170S204 · doi:10.1177/03946320040170s204
  6. Lucchini, 2000, Assessment of neurobehavioral performance as a function of current and cumulative occupational lead exposure, Neurotoxicology, 21, 805
  7. Alessio, 2006, Prolactin changes as a consequence of chemical exposure, Environ Health Perspect, 114, A573, 10.1289/ehp.114-a573 · doi:10.1289/ehp.114-a573
  8. Waschek, 1987, Barium distinguishes separate calcium targets for synthesis and secretion of peptides in neuroendocrine cells, Biochem Biophys Res Commun, 146, 495, 10.1016/0006-291X(87)90556-0 · doi:10.1016/0006-291x(87)90556-0
  9. Vrkljan, 2006, Incidence of pituitary tumors in the human population of Croatia, Coll Antropol, 30, 157
  10. Zargar, 2004, Clinical and endocrine aspects of pituitary tumors, Saudi Med J, 25, 1428
  11. Fideleff, 2000, Peripubertal prolactinoma: clinical presentation and long-term outcome with different therapeutic approaches, J Pediatr Endocrinol Metab, 13, 261, 10.1515/JPEM.2000.13.3.261 · doi:10.1515/jpem.2000.13.3.261
  12. Mindermann, 1995, Pituitary adenomas in childhood and adolescence, J Pediatr Endocrinol Metab, 8, 79, 10.1515/JPEM.1995.8.2.79 · doi:10.1515/jpem.1995.8.2.79
  13. Daly, 2006, Clinical characterization of familial isolated pituitary adenomas, J Clin Endocrinol Metab, 91, 3316, 10.1210/jc.2005-2671 · doi:10.1210/jc.2005-2671
  14. Karga, 1992, Ras mutations in human pituitary tumors, J Clin Endocrinol Metab, 74, 914, 10.1210/jcem.74.4.1312542 · doi:10.1210/jcem.74.4.1312542
  15. Cristina, 2007, PTTG expression in different experimental and human prolactinoma in relation to dopaminergic control of lactotropes, Mol Cancer, 6, 1, 10.1186/1476-4598-6-4 · doi:10.1186/1476-4598-6-4
  16. Horwitz, 2003, Human pituitary tumor-transforming gene (PTTG1) motif suppresses PRL expression, Mol Endocrinol, 17, 600, 10.1210/me.2001-0006 · doi:10.1210/me.2001-0006
  17. Sigala, 2004, Increased serum concentration of nerve growth factor in patients with microprolactinoma, Neuropeptides, 38, 21, 10.1016/j.npep.2003.11.002 · doi:10.1016/j.npep.2003.11.002
  18. Smith, 2007, Technology insight: measuring PRL in clinical samples, Nat Clin Pract Endocrinol Metab, 3, 279, 10.1038/ncpendmet0447 · DOI
  19. Quinn, 2006, Determination of ultrafilterable PRL: elimination of macroprolactin interference with a monomeric PRL-selective sample pretreatment, Arch Pathol Lab Med, 130, 1807, 10.5858/2006-130-1807-DOUPEO · doi:10.5858/2006-130-1807-doupeo
  20. Hauache, 2002, Screening for macroprolactinaemia and pituitary imaging studies, Clin Endocrinol (Oxf), 57, 327, 10.1046/j.1365-2265.2002.01586.x · doi:10.1046/j.1365-2265.2002.01586.x
  21. Ambrosi, 1980, PRL and sexual function, JAMA, 244, 2608, 10.1001/jama.1980.03310230014010 · doi:10.1001/jama.1980.03310230014010
  22. Orrego, 2000, Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine, Pituitary, 3, 189, 10.1023/A:1011412028660 · doi:10.1023/a:1011412028660
  23. Wass, 2006, When to discontinue treatment of prolactinoma?, Nat Clin Pract Endocrinol Metab, 2, 298, 10.1038/ncpendmet0162 · doi:10.1038/ncpendmet0162
  24. Bronstein, 2006, Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy, Nat Clin Pract Endocrinol Metab, 2, 130, 10.1038/ncpendmet0135 · doi:10.1038/ncpendmet0135
  25. Crosignani, 1978, Antiserotonin treatment of hyperprolactinemic amenorrhea: long-term follow-up with metergoline, methysergide, and cyproheptadine, Am J Obstet Gynecol, 132, 307, 10.1016/0002-9378(78)90898-0 · doi:10.1016/0002-9378(78)90898-0
  26. Bohnet, 1986, Treatment of hyperprolactinemic amenorrhea with Metergoline, Obstet Gynecol, 67, 249, 10.1097/00006250-198602000-00016 · doi:10.1097/00006250-198602000-00016
  27. Weiss, 1983, Bromocriptine treatment of PRL-secreting tumors: surgical implications, Neurosurgery, 12, 640, 10.1227/00006123-198306000-00008 · doi:10.1227/00006123-198306000-00008
  28. Kissner, 1980, Side effects of bromocriptine, N Engl J Med, 302, 749, 10.1056/NEJM198003273021313 · doi:10.1056/nejm198003273021313
  29. Pearson, 1981, Mental disorders from low-dose bromocriptine, N Engl J Med, 305, 173, 10.1056/NEJM198107163050321 · doi:10.1056/nejm198107163050321
  30. Baskin, 1982, CSF rhinorrhea after bromocriptine for prolactinoma, N Engl J Med, 306, 178, 10.1056/NEJM198201213060322 · doi:10.1056/nejm198201213060322
  31. Franks, 1981, Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment, Lancet, 2, 659, 10.1016/S0140-6736(81)90997-1 · doi:10.1016/s0140-6736(81)90997-1
  32. Giusti, 1994, A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients, J Endocrinol Invest, 17, 51, 10.1007/BF03344963 · doi:10.1007/bf03344963
  33. Jaquet, 1999, Quantitative and functional expression of somatostatin receptor subtypes in human prolactinoma, J Clin Endocrinol Metab, 84, 3268
  34. Jaquet, 2005, Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and PRL secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy, Eur J Endocrinol, 153, 135, 10.1530/eje.1.01950 · doi:10.1530/eje.1.01950
  35. Cappabianca, 2004, Endoscopic endonasal transsphenoidal surgery, Neurosurgery, 55, 933, 10.1227/01.NEU.0000137330.02549.0D · doi:10.1227/01.neu.0000137330.02549.0d
  36. Thomson, 1994, Ten year follow up of microprolactinoma treated by transsphenoidal surgery, BMJ, 309, 1409, 10.1136/bmj.309.6966.1409 · doi:10.1136/bmj.309.6966.1409
  37. Amar, 2002, Predictive value of serum PRL levels measured immediately after transsphenoidal surgery, J Neurosurg, 97, 307, 10.3171/jns.2002.97.2.0307 · doi:10.3171/jns.2002.97.2.0307
  38. Landolt, 1982, Bromocriptine: does it jeopardise the result of later surgery for prolactinoma?, Lancet, 2, 657, 10.1016/S0140-6736(82)92756-8 · doi:10.1016/s0140-6736(82)92756-8
  39. Fahlbusch, 1984, Influence of preoperative bromocriptine therapy on success of surgery for microprolactinoma, Lancet, 2, 520, 10.1016/S0140-6736(84)92596-0 · doi:10.1016/s0140-6736(84)92596-0
  40. Kuo, 2004, Gamma knife radiosurgery for benign cavernous sinus tumors: quantitative analysis of treatment outcomes, Neurosurgery, 54, 1385, 10.1227/01.NEU.0000124750.13721.94 · doi:10.1227/01.neu.0000124750.13721.94
  41. Landolt, 2000, Gamma knife radiosurgery for prolactinoma, J Neurosurg, 93, 14, 10.3171/jns.2000.93.supplement_3.0014 · doi:10.3171/jns.2000.93.supplement_3.0014
  42. Ahmed, 1992, Macroprolactinoma with suprasellar extension: effect of bromocriptine withdrawal during one or more pregnancies, Fertil Steril, 58, 492, 10.1016/S0015-0282(16)55250-9 · doi:10.1016/s0015-0282(16)55250-9

Cited by

See all 256

Metadata

Authors
Mancini, T., Casanueva, F. F., & Giustina, A.
Venue
Endocrinology and Metabolism Clinics of North America
Publisher
Elsevier BV
Published
2008-03
Volume
37
Issue
1
Pages
67-99
ISSN
0889-8529 (ISSN-L)
OpenAlex
W2073194318
Cited by
256
References
157
FWCI
11.11
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.